|----------|----------------------------------------------------------------------------------|

**Indication**
- Necrotising fasciitis
  - **ICD11 code:** 1B71.Z

**INN**
- Metronidazole

**Medicine type**
- Chemical agent

**Antibiotic groups**
- ACCESS

**List type**
- Core (EML)
  - (EMLc)

**Formulations**
- **Oral > Liquid**:
  - 200 mg per 5 mL (as benzoate)
- **Local > Rectal > Suppository**:
  - 500 mg (EML);
  - 1 g (EML)
- **Parenteral > General injections > unspecified**:
  - 500 mg per 100 mL in vial
- **Oral > Solid > tablet**:
  - 200 mg;
  - 250 mg;
  - 400 mg;
  - 500 mg

**EML status history**
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
  - Read more about patents.

**Wikipedia**
- Metronidazole

**DrugBank**
- Metronidazole

---

**Expert Committee recommendation**

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc.

The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc
- the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc
- the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

**EML recommendations: Necrotising fasciitis**

**First choice**
- Metronidazole

**Second choice**
<table>
<thead>
<tr>
<th>Medicine</th>
<th>Prescription with</th>
</tr>
</thead>
<tbody>
<tr>
<td>clindamycin</td>
<td>piperacillin + tazobactam</td>
</tr>
<tr>
<td>vancomycin</td>
<td></td>
</tr>
<tr>
<td>metronidazole</td>
<td>ceftriaxone</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ceftriaxone</td>
</tr>
</tbody>
</table>